• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诱导多能干细胞(iPSCs)在神经退行性疾病治疗中的变革性工具:幻影还是现实?

Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: Mirage or reality?

机构信息

Department of Physiology and Pharmacology, Pasteur Instittableute of Iran, Tehran, Iran.

Stem Cell and Regenerative Medicine Center, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

J Cell Physiol. 2020 Dec;235(12):9166-9184. doi: 10.1002/jcp.29800. Epub 2020 May 21.

DOI:10.1002/jcp.29800
PMID:32437029
Abstract

Based on investigations, there exist tight correlations between neurodegenerative diseases' incidence and progression and aberrant protein aggregreferates in nervous tissue. However, the pathology of these diseases is not well known, leading to an inability to find an appropriate therapeutic approach to delay occurrence or slow many neurodegenerative diseases' development. The accessibility of induced pluripotent stem cells (iPSCs) in mimicking the phenotypes of various late-onset neurodegenerative diseases presents a novel strategy for in vitro disease modeling. The iPSCs provide a valuable and well-identified resource to clarify neurodegenerative disease mechanisms, as well as prepare a promising human stem cell platform for drug screening. Undoubtedly, neurodegenerative disease modeling using iPSCs has established innovative opportunities for both mechanistic types of research and recognition of novel disease treatments. Most important, the iPSCs have been considered as a novel autologous cell origin for cell-based therapy of neurodegenerative diseases following differentiation to varied types of neural lineage cells (e.g. GABAergic neurons, dopamine neurons, cortical neurons, and motor neurons). In this review, we summarize iPSC-based disease modeling in neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease. Moreover, we discuss the efficacy of cell-replacement therapies for neurodegenerative disease.

摘要

基于研究,神经退行性疾病的发病率和进展与神经组织中异常的蛋白质聚集物之间存在紧密的相关性。然而,这些疾病的病理学尚不清楚,导致无法找到适当的治疗方法来延迟发生或减缓许多神经退行性疾病的发展。诱导多能干细胞(iPSC)在模拟各种迟发性神经退行性疾病表型方面的可及性为体外疾病建模提供了一种新策略。iPSC 为阐明神经退行性疾病机制提供了宝贵且明确的资源,并为药物筛选准备了有前途的人类干细胞平台。毫无疑问,使用 iPSC 进行神经退行性疾病建模为机制研究和新型疾病治疗方法的识别开辟了创新机会。最重要的是,iPSC 被认为是神经退行性疾病基于细胞的治疗的新型自体细胞起源,可以分化为各种神经谱系细胞(例如 GABA 能神经元、多巴胺神经元、皮层神经元和运动神经元)。在这篇综述中,我们总结了基于 iPSC 的神经退行性疾病模型,包括阿尔茨海默病、肌萎缩侧索硬化症、帕金森病和亨廷顿病。此外,我们还讨论了细胞替代疗法治疗神经退行性疾病的效果。

相似文献

1
Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: Mirage or reality?诱导多能干细胞(iPSCs)在神经退行性疾病治疗中的变革性工具:幻影还是现实?
J Cell Physiol. 2020 Dec;235(12):9166-9184. doi: 10.1002/jcp.29800. Epub 2020 May 21.
2
Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.利用多能干细胞技术对人类神经退行性疾病进行逆向工程研究。
Brain Res. 2016 May 1;1638(Pt A):30-41. doi: 10.1016/j.brainres.2015.09.023. Epub 2015 Sep 28.
3
Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.用于神经退行性疾病建模和药物发现的诱导多能干细胞
Mol Neurobiol. 2015 Aug;52(1):244-55. doi: 10.1007/s12035-014-8867-6. Epub 2014 Aug 23.
4
Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations.人类多能干细胞在神经退行性疾病中的应用:潜力、进展与局限。
Curr Stem Cell Res Ther. 2020;15(2):102-110. doi: 10.2174/1574888X14666190823142911.
5
The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases.诱导多能干细胞在再生医学中的作用:神经退行性疾病。
Stem Cell Res Ther. 2011 Jul 28;2(4):32. doi: 10.1186/scrt73.
6
Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases.人诱导多能干细胞在神经退行性疾病建模和治疗中的应用。
N Biotechnol. 2015 Jan 25;32(1):212-28. doi: 10.1016/j.nbt.2014.05.001. Epub 2014 May 9.
7
Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies.人诱导多能干细胞与神经退行性疾病:新型疗法的前景。
Curr Opin Neurol. 2012 Apr;25(2):125-30. doi: 10.1097/WCO.0b013e3283518226.
8
The application of iPSCs in Parkinson's disease.iPSCs 在帕金森病中的应用。
Acta Neurobiol Exp (Wars). 2020;80(3):273-285.
9
Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease.诱导多能干细胞在神经退行性疾病建模中的应用机遇与挑战。
Open Biol. 2019 Jan 31;9(1):180177. doi: 10.1098/rsob.180177.
10
Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy.诱导多能干细胞技术在神经疾病建模、药物筛选和治疗中的进展。
Curr Stem Cell Res Ther. 2024;19(6):809-819. doi: 10.2174/1574888X18666230608105703.

引用本文的文献

1
Frontiers of stem cell engineering for nanotechnology-mediated drug delivery systems.用于纳米技术介导的药物递送系统的干细胞工程前沿
ADMET DMPK. 2024 Feb 14;12(2):225-237. doi: 10.5599/admet.2160. eCollection 2024.
2
Advancements in Autologous Stem Cell Transplantation for Parkinson's Disease.帕金森病自体干细胞移植的进展
Curr Stem Cell Res Ther. 2024;19(10):1321-1327. doi: 10.2174/1574888X19666230907112413.
3
Development of brain organoid technology derived from iPSC for the neurodegenerative disease modelling: a glance through.
用于神经退行性疾病建模的源自诱导多能干细胞的脑类器官技术的发展:概览
Front Mol Neurosci. 2023 Aug 3;16:1173433. doi: 10.3389/fnmol.2023.1173433. eCollection 2023.
4
Current Treatments and New, Tentative Therapies for Parkinson's Disease.帕金森病的当前治疗方法及新的试验性疗法
Pharmaceutics. 2023 Feb 25;15(3):770. doi: 10.3390/pharmaceutics15030770.
5
Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.针对功能获得性毒性神经退行性疾病的个性化等位基因特异性反义寡核苷酸疗法
Pharmaceutics. 2022 Aug 16;14(8):1708. doi: 10.3390/pharmaceutics14081708.
6
hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible.人诱导多能干细胞在神经退行性疾病预测模型中的应用:梦想成真。
Nat Rev Neurol. 2021 Jun;17(6):381-392. doi: 10.1038/s41582-021-00465-0. Epub 2021 Mar 3.